MDCX

Medicus Pharma Ltd.

Insider activity for last month from 08/09 to 09/09. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Latest filingSep 08, 2026Most recent Form 4
Total buying$00 buys
Total selling$00 sells
Net open-market+$05 insiders
Open-market mix
Buy vs sell distribution by transaction count
0 transactions

Insider activity report

Monthly open-market purchase and sale counts
Buys Sells
530-3-5transactionsAugSep

Transaction codes

By Form 4 transaction code in selected period
10transactions
  • A · Grants / awards · dominant10 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
10transactions
  • Chief executive officer · dominant2 · 20%
  • CMO2 · 20%
  • COO2 · 20%
  • CSO2 · 20%
  • PRES2 · 20%

Distinct insiders active

Reporting-owner CIKs by month · peak Sep 2026 (5)
Aug 2026Sep 2026
5distinct insiders in 2 months

Reported Holdings After

Separated by insider, security, and ownership type
Bokhari RazaCommon Shares, no par value · Direct
2.9M2.9MSep 04, 2026 · 2,941,176 shares owned afterSep 04, 2026Sep 04, 2026
2,941,176Sep 04, 2026
Bokhari RazaStock Option (right to buy) · Direct
500.0k500.0kSep 04, 2026 · 500,000 shares owned afterSep 04, 2026Sep 04, 2026
500,000Sep 04, 2026
Bonner Carolyn F.Common Shares, no par value · Direct
1.5M1.5MSep 04, 2026 · 1,489,493 shares owned afterSep 04, 2026Sep 04, 2026
1,489,493Sep 04, 2026
Bonner Carolyn F.Stock Option (right to buy) · Direct
250.0k250.0kSep 04, 2026 · 250,000 shares owned afterSep 04, 2026Sep 04, 2026
250,000Sep 04, 2026
Brennan Edward J.Stock Option (right to buy) · Direct
100.0k100.0kSep 04, 2026 · 100,000 shares owned afterSep 04, 2026Sep 04, 2026
100,000Sep 04, 2026
Brennan Edward J.Common Shares, no par value · Direct
674.7k674.7kSep 04, 2026 · 674,735 shares owned afterSep 04, 2026Sep 04, 2026
674,735Sep 04, 2026
Mehmud FaisalStock Option (right to buy) · Direct
250.0k250.0kSep 04, 2026 · 250,000 shares owned afterSep 04, 2026Sep 04, 2026
250,000Sep 04, 2026
Mehmud FaisalCommon Shares, no par value · Direct
1.5M1.5MSep 04, 2026 · 1,470,588 shares owned afterSep 04, 2026Sep 04, 2026
1,470,588Sep 04, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells red
0 active days
Aug 09Sep 09
LessMore

Filing detail checks

Secondary metrics for the selected period
Largest buy-
Largest sale-
10b5-1 detected0
Amended rows0

Filing-only signals

Deterministic matches in the selected period

No filing-only signal badges matched this period.

MDCX transaction history

Filters apply within this company and selected period by default
Reset
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date

No transactions match your filters

Once the backend ingests and parses SEC filings, they will appear here. Try removing a filter or picking a wider date range.

Medicus Pharma Ltd. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Medicus Pharma Ltd.?

Smith Andrew Alasdair, Mehmud Faisal, Brennan Edward J., Bonner Carolyn F., Bokhari Raza.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

No code-P purchases or code-S sales were reported in the selected period.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.